Abiopharma

New Form D - Akari Therapeutics Plc Filed: 2025-10-24 AccNo: 0001493152-25-019187 Size: 14 KB

(85% Positive) Aprea Therapeutics, Inc. (APRE) Announces Enrollment Update for Inhibitor Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

Lilly to Acquire Adverum Biotechnologies

Aprea Therapeutics Provides Clinical Update from ACESOT-1051 Trial Showing Early Signals of Activity for WEE1 Kinase Inhibitor APR-1051

Journey Medical Corporation Reports Combined Emrosi™(DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference

Journey Medical Corporation Reports Combined Emrosi™(DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference

Actinium Pharmaceuticals Presents New Data Demonstrating Potent and Durable Efficacy of ATNM-400, a First-in-Class Multi-Tumor Actinium-225 Radiotherapy, at the 32nd Annual Prostate Cancer Foundation Scientific Retreat

FibroBiologics to Present at Bio-Europe 2025

New Form 424B5 - Genprex, Inc. Filed: 2025-10-24 AccNo: 0001437749-25-031677 Size: 503 KB

(99% Neutral) GENPREX, INC. (GNPX) Provides Update on exercise for full of short-term warrants AUSTIN

(70% Positive) Neuraxis, Inc. (NRXS) Announces Clinical Development Update

New Form DEF 14A - CorMedix Inc. Filed: 2025-10-24 AccNo: 0001213900-25-101906 Size: 3 MB

Halper Sadeh LLC Encourages BioVie Inc. Shareholders to Contact the Firm to Discuss Their Rights

(99% Neutral) Cassava Sciences, Inc. (SAVA) Announces Clinical Development Update

Johnson & Johnson - Icotrokinra long-term results affirm promise of targeted oral peptide with high rates of durable skin clearance and favorable safety profile in difficult-to-treat scalp and genital psoriasis